Medtronic CE marks DBS therapy for epilepsy
This article was originally published in Clinica
Medtronic has CE marked its deep brain stimulation (DBS) therapy for sale in Europe as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. The device delivers electrical pulses to the anterior nucleus of the thalamus, which is part of a neurological circuit involved in seizures, and will be released to "expert epilepsy centres across Europe" by the end of the year, Medtronic said. Use of the product for epilepsy is under review by the US FDA, which recently requested additional clinical data to support Medtronic’s premarket approval (PMA) application. Medtronic DBS therapy is currently approved in Europe and the US for the treatment of the disabling symptoms of essential tremor and advanced Parkinson's disease. It is approved in Europe for dystonia and obsessive-compulsive disorder (OCD), and in the US the use of DBS for dystonia and treatment-resistant OCD is approved under a Humanitarian Device Exemption (HDE).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.